Search

Your search keyword '"Branch, Kelley R.H."' showing total 16 results
Start Over Author "Branch, Kelley R.H." Publication Type Academic Journals
16 results on '"Branch, Kelley R.H."'

5. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

Author

Moayyedi, Paul, Eikelboom, John W., Bosch, Jackie, Connolly, Stuart J., Dyal, Leanne, Shestakovska, Olga, Leong, Darryl, Anand, Sonia S., Störk, Stefan, Branch, Kelley R.H., Bhatt, Deepak L., Verhamme, Peter B., O’Donnell, Martin, Maggioni, Aldo P., Lonn, Eva M., Piegas, Leopoldo S., Ertl, Georg, Keltai, Matyas, Bruns, Nancy Cook, Muehlhofer, Eva, Dagenais, Gilles R., Kim, Jae-Hyung, Hori, Masatsugu, Steg, P. Gabriel, Hart, Robert G., Diaz, Rafael, Alings, Marco, Widimsky, Petr, Avezum, Alvaro, Probstfield, Jeffrey, Zhu, Jun, Liang, Yan, Lopez-Jaramillo, Patricio, Kakkar, Ajay K., Parkhomenko, Alexander N., Ryden, Lars, Pogosova, Nana, Dans, Antonio L., Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomek J., Vinereanu, Dragos, Tonkin, Andrew M., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Metsarinne, Kaj P., Fox, Keith A.A., and Yusuf, Salim

Published
2019
Full Text
View/download PDF

8. Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy

Author

Sharma, Mukul, Hart, Robert G., Smith, Eric E., Bosch, Jacqueline, Eikelboom, John W., Connolly, Stuart J., Dyal, Leanne, Reeh, Kevin W, Casanova, Amparo, Diaz, Rafael, Lopez-Jaramillo, Patricio, Ertl, Georg, Störk, Stefan, Dagenais, Gilles R., Lonn, Eva M., Ryden, Lars, Tonkin, Andrew M., Varigos, John D., Bhatt, Deepak L., Branch, Kelley R.H., Probstfield, Jeffrey L., Kim, Jae-Hyung, O’Donnell, Martin, Vinereanu, Dragos, Fox, Keith A.A., Liang, Yan, Liu, Lisheng, Zhu, Jun, Pogosova, Nana, Maggioni, Aldo P., Avezum, Alvaro, Piegas, Leopoldo S., Keltai, Katalin, Keltai, Matyas, Berkowitz, Scott D., and Yusuf, Salim

Published
2020
Full Text
View/download PDF

9. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial

Author

Bosch, Jackie, Eikelboom, John W., Connolly, Stuart J., Bruns, Nancy Cook, Lanius, Vivian, Yuan, Fei, Misselwitz, Frank, Chen, Edmond, Diaz, Rafael, Alings, Marco, Lonn, Eva M., Widimsky, Petr, Hori, Masatsugu, Avezum, Alvaro, Piegas, Leopoldo S., Bhatt, Deepak L., Branch, Kelley R.H., Probstfield, Jeffrey L., Liang, Yan, Liu, Lisheng, Zhu, Jun, Maggioni, Aldo P., Lopez-Jaramillo, Patricio, O'Donnell, Martin, Fox, Keith A.A., Kakkar, Ajay, Parkhomenko, Alexander N., Ertl, Georg, Störk, Stefan, Keltai, Katalin, Keltai, Matyas, Ryden, Lars, Dagenais, Gilles R., Pogosova, Nana, Dans, Antonio L., Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomasz J., Verhamme, Peter B., Vinereanu, Dragos, Kim, Jae-Hyung, Ha, Jong-Won, Tonkin, Andrew M., Varigos, John D., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Steg, Philippe Gabriel, Aboyans, Victor, Metsarinne, Kaj P., Anand, Sonia S., Hart, Robert G., Lamy, Andre, Moayyedi, Paul, Leong, Darryl P., Sharma, Mukul, and Yusuf, Salim

Published
2017
Full Text
View/download PDF

10. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

Author

Bhatt, Deepak L., Eikelboom, John W., Connolly, Stuart J., Steg, P. Gabriel, Anand, Sonia S., Verma, Subodh, Branch, Kelley R.H., Probstfield, Jeffrey, Bosch, Jackie, Shestakovska, Olga, Szarek, Michael, Maggioni, Aldo Pietro, Widimský, Petr, Avezum, Alvaro, Diaz, Rafael, Lewis, Basil S., Berkowitz, Scott D., Fox, Keith A.A., Ryden, Lars, and Yusuf, Salim

Published
2020
Full Text
View/download PDF

11. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

Author

Eikelboom, John W., Connolly, Stuart J., Bosch, Jackie, Dagenais, Gilles R., Hart, Robert G., Shestakovska, Olga, Diaz, Rafael, Alings, Marco, Lonn, Eva M., Anand, Sonia S., Widimsky, Petr, Hori, Masatsugu, Avezum, Alvaro, Piegas, Leopoldo S., Branch, Kelley R.H., Probstfield, Jeffrey, Bhatt, Deepak L., Zhu, Jun, Liang, Yan, Maggioni, Aldo P., Lopez-Jaramillo, Patricio, OʼDonnell, Martin, Kakkar, Ajay K., Fox, Keith A.A., Parkhomenko, Alexander N., Ertl, Georg, Störk, Stefan, Keltai, Matyas, Ryden, Lars, Pogosova, Nana, Dans, Antonio L., Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomek J., Verhamme, Peter B., Vinereanu, Dragos, Kim, Jae-Hyung, Tonkin, Andrew M., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Steg, Gabriel P., Metsarinne, Kaj P., Bruns, Nancy Cook, Misselwitz, Frank, Chen, Edmond, Leong, Darryl, and Yusuf, Salim

Published
2017
Full Text
View/download PDF

12. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial.

Author

Branch, Kelley R.H., Dagenais, Gilles R., Avezum, Alvaro, Basile, Jan, Conget, Ignacio, Cushman, William C., Jansky, Petr, Lakshmanan, Mark, Lanas, Fernando, Leiter, Lawrence A., Pais, Prem, Pogosova, Nana, Raubenheimer, Peter J., Ryden, Lars, Shaw, Jonathan E., Sheu, Wayne H.H., Temelkova‐Kurktschiev, Theodora, Bethel, M. Angelyn, Gerstein, Hertzel C., and Chinthanie, Ramasundarahettige

Abstract

Aims: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon‐like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo‐controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Methods and results: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non‐fatal myocardial infarction, non‐fatal stroke, or death from cardiovascular causes (including unknown causes). In this post‐hoc analysis, a HF event was defined as an adjudication‐confirmed hospitalization or urgent evaluation for HF. Of the 9901 participants studied over a median follow‐up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a HF event (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.77–1.12; p = 0.456). In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF (p = 0.44 and 0.19 for interaction, respectively). Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78–1.00; p = 0.050) but unchanged in patients with and without HF at baseline (p = 0.31). Conclusions: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow‐up. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial'.

Author

Branch, Kelley R.H., Gerstein, Hertzel C., and Probstfield, Jeffrey L.

Subjects
*HEART failure patients, *VENTRICULAR ejection fraction, *FAILURE analysis, *GLUCAGON-like peptide-1 receptor
Abstract

Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. We thank Dr's Ferriera and Neves for their response to our recent post-hoc analysis of the REWIND trial and their interest in further analysis of the subgroup of patients that had a history of heart failure (HF), but did not have HF at the baseline visit.[1] HF is a heterogeneous diagnosis with variable prognosis depending on a number of variables such as cardiac function, medical and device therapy, concomitant diseases and functional status.[[2]] The authors correctly point out that there was a relatively low proportion of patients that were diagnosed as having HF at baseline (8.6%) compared to other glucagon-like peptide 1 receptor agonist studies.[[4], [6]] Possible explanations for this difference may lie in the lower risk population from REWIND as compared to the other studies and the fact that HF was not a criterion for entry into the study.[8] Further, as described as a limitation in the manuscript, HF at baseline was determined by the site primary investigators who were not required to provide supporting data such as ejection fraction, brain natriuretic peptide, or history of HF hospitalizations. Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'. [Extracted from the article]

Published
2022
Full Text
View/download PDF

16. Scoping review of echocardiographic parameters associated with diagnosis and prognosis after resuscitated sudden cardiac arrest.

Author

Liu, Linda, Karatasakis, Aris, Kudenchuk, Peter J., Kirkpatrick, James N., Sayre, Michael R., Carlbom, David J., Johnson, Nicholas J., Probstfield, Jeffrey L., Counts, Catherine, and Branch, Kelley R.H.

Subjects
*CARDIAC arrest, *RIGHT ventricular dysfunction, *ECHOCARDIOGRAPHY, *PROGNOSIS, *SUDDEN death, *SURVIVAL analysis (Biometry)
Abstract

Current international guidelines recommend early echocardiography after resuscitated sudden death despite limited data. Our aim was to analyze published data on early post-resuscitation echocardiography to identify cardiac causes of sudden death and prognostic implications. We reviewed MEDLINE, EMBASE, and CENTRAL databases to December 2021 for echocardiographic studies of adult patients after resuscitation from non-traumatic sudden death. Studies were included if echocardiography was performed <48 hours after resuscitation and reported (1) diagnostic accuracy to detect cardiac etiologies of sudden death or (2) prognostic outcomes. Diagnostic endpoints were associations of regional wall motion abnormalities (RWMA), ventricular function, and structural abnormalities with cardiac etiologies of arrest. Prognostic endpoints were associations of echocardiographic findings with survival to hospital discharge and favorable neurological outcome. Of 2877 articles screened, 16 (0.6%) studies met inclusion criteria, comprising 2035 patients. Two of six studies formally reported diagnostic accuracy for echocardiography identifying cardiac etiology of arrest; RWMA (in 5 of 6 studies) were associated with presumed cardiac ischemia in 17–89% of cases. Among 12 prognostic studies, there was no association of reduced left ventricular ejection fraction with hospital survival (v10) or favorable neurologic status (n = 5). Echocardiographic high mitral E/e′ ratio (n = 1) and right ventricular systolic dysfunction (n = 2) were associated with poor survival. This scoping review highlights the limited data on early echocardiography in providing etiology of arrest and prognostic information after resuscitated sudden death. Further research is needed to refine the clinical application of early echocardiographic findings in post arrest care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results